Ted Pharmaceuticals Pari osteobolicol injections are approved for drug registration

Recently, Beijing Ted Pharmaceutical Co., Ltd. independently developed Pari orthosterol injection (commodity name: Kesha) officially obtained the State Drug Administration of the People's Republic of China issued a drug registration certificate.
Pali osteoporosisol is the latest generation of selective vitamin D-receiving excitants, combined with vitamin D-recipients to effectively reduce thyroid hormone (PTH), which is delivered through hemodialysis pathopathy to treat secondary thyroid hyperthyroidism in patients with chronic renal failure who receive hemodialysis.
Thyroid hyperthyroidism is the secretion of excessive thyroid hormones in the nail-like side glands, which can lead to bone pain, fractures, hypercalcemia, etc., harming many other systems of the body, such as the heart circulation system, neuromuscular motor system, digestive system and central nervous system, etc., need active diagnosis and treatment.
according to statistics, in China, the incidence of chronic kidney disease (CKD) as high as 10.8%, of which, nearly 30 million patients will develop into end-stage kidney disease, need dialysis treatment, in the course of dialysis treatment will appear hyperthyroidism, high calcium, high phosphorus and other symptoms.
As a drug of choice for treating hyperthyroidism caused by chronic kidney dialysis, Pari osteosterol has been widely used in Europe and the United States, which has a small impact on calcium and phosphorus while reducing PTH, and can also reduce the risk of calcification, reduce the risk of calcification, reduce the risk of death, long-term use can significantly improve the survival rate of patients.
Kaisha's approval will further expand the Group's product pipeline in the field of renal medicine, for the vast number of patients with kidney failure to bring the best treatment options!